<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918332</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VRCL002</org_study_id>
    <nct_id>NCT01918332</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia</brief_title>
  <official_title>A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of the coadministration of valsartan
      (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered
      alone in patients with hypertension and hyperlipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sitDBP Changes at Week 8 From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-C Percentage Changes at Week 8 From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Hypertension,</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160mg placebo, Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg</intervention_name>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg placebo</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo, Rosuvastatin 20mg</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg placebo</intervention_name>
    <arm_group_label>Valsartan 160mg placebo, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg placebo</intervention_name>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged 20-80 years who has hypertension and hyperlipidemia

          2. Patient who has a Hypertension

          3. Patient who has a Hyperlipidemia according to NCEP-ATP III guideline(2004)

          4. Patient who signed the Informed Consent Form after receiving an explanation on the
             purpose, methods, and effect of the study

        Exclusion Criteria:

          1. If blood pressure and fasting serum lipid level measured at screening and Visit 2 (0
             week) satisfy the following criteria 1) sitSBP≥180mmHg or sitDBP≥110mmHg (For high
             risk group, sitSBP≥ 160mmHg or sitDBP ≥100mmHg ) 2) LDL-C&gt;250mg/dL , or TG≥ 400mg/dL

          2. If sitSBP difference between the right and left arms &gt;20mmHg or sitDBP difference
             between the right and left arms &gt; 10mmHg at screening

          3. When blood pressure is repeatedly measured from the selected arm at screening, if
             sitSBP difference ≥ 20mmHg or sitDBP difference ≥10mmHg

          4. Patient with orthostatic hypotension accompanying symptoms at screening (decrease in
             sitDBP ≥10mmHg or decrease in sitSBP ≥ 20mmHg )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei University Health System Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <results_first_submitted>April 24, 2014</results_first_submitted>
  <results_first_submitted_qc>December 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2014</results_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valsartan 160mg, Rosuvastatin 20mg</title>
          <description>Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
Valsartan 160mg
Rosuvastatin 20mg</description>
        </group>
        <group group_id="P2">
          <title>Valsartan 160mg, Rosuvastatin 20mg Placebo</title>
          <description>Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Valsartan 160mg
Rosuvastatin 20mg placebo</description>
        </group>
        <group group_id="P3">
          <title>Valsartan 160mg Placebo, Rosuvastatin 20mg</title>
          <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
Rosuvastatin 20mg
Valsartan 160mg placebo</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Valsartan 160mg placebo
Rosuvastatin 20mg placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>lipid result by central lab did not meet</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>Valsartan 160mg, Rosuvastatin 20mg</title>
          <description>Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
Valsartan 160mg
Rosuvastatin 20mg</description>
        </group>
        <group group_id="B2">
          <title>Valsartan 160mg, Rosuvastatin 20mg Placebo</title>
          <description>Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Valsartan 160mg
Rosuvastatin 20mg placebo</description>
        </group>
        <group group_id="B3">
          <title>Valsartan 160mg Placebo, Rosuvastatin 20mg</title>
          <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
Rosuvastatin 20mg
Valsartan 160mg placebo</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Valsartan 160mg placebo
Rosuvastatin 20mg placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>sitDBP Changes at Week 8 From Baseline</title>
        <description>sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>V160+R20 &amp; V160</title>
            <description>Valsartan 160mg + Rosuvastatin 20mg &amp; Valsartan 160mg + Rosuvastatin 20mg placebo</description>
          </group>
          <group group_id="O2">
            <title>R20 &amp; Placebo</title>
            <description>Valsartan 160mg placebo + Rosuvastatin 20mg &amp; Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>sitDBP Changes at Week 8 From Baseline</title>
          <description>sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline</description>
          <population>FAS</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.24" lower_limit="-10.88" upper_limit="-7.61"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-4.55" upper_limit="-1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LDL-C Percentage Changes at Week 8 From Baseline</title>
        <description>LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>V160+R20 &amp; R20</title>
            <description>Valsartan 160mg + Rosuvastatin 20mg &amp; Valsartan 160mg placebo + Rosuvastatin 20mg</description>
          </group>
          <group group_id="O2">
            <title>V160 &amp; Placebo</title>
            <description>Valsartan 160mg + Rosuvastatin 20mg placebo &amp; Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-C Percentage Changes at Week 8 From Baseline</title>
          <description>LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline</description>
          <population>FAS</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.91" lower_limit="-53.34" upper_limit="-46.47"/>
                    <measurement group_id="O2" value="-2.38" lower_limit="-5.65" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12~14 weeks (4-6 weeks of Therapeutic Lifestyle Change + 8 weeks of Treatment period)</time_frame>
      <desc>All adverse events were collected at every visit by interview, physical assessment and laboratory tests .
The following other AE table presents the subject numbers of AE in the first line in the table and the case numbers of AE in the other rows respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Valsartan 160mg, Rosuvastatin 20mg</title>
          <description>Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
Valsartan 160mg
Rosuvastatin 20mg</description>
        </group>
        <group group_id="E2">
          <title>Valsartan 160mg, Rosuvastatin 20mg Placebo</title>
          <description>Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Valsartan 160mg
Rosuvastatin 20mg placebo</description>
        </group>
        <group group_id="E3">
          <title>Valsartan 160mg Placebo, Rosuvastatin 20mg</title>
          <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
Rosuvastatin 20mg
Valsartan 160mg placebo</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
Valsartan 160mg placebo
Rosuvastatin 20mg placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>The subject participated in the study on 17 Sep 2012, and she was randomized on 18 Oct 2012. On that day, the subject had nausea and chest pain after eating cake, and visited the institution and was hospitalized on 22 Oct 2012.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngisit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Withdrawal(discontinuation) leading to smaller number of per-protocol set than full analysis set. The violation of protocol was the criterion of subjects' withdrawal.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. YangSoo Jang</name_or_title>
      <organization>Yonsei University Healthcare System Severance Hospital</organization>
      <phone>82-2-6924-3109</phone>
      <email>yejung@lgls.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

